BITT develops a novel class of antagonist monoclonal antibodies against TNF superfamily receptors using its DOMab™ platform. Its lead candidate, BIR2101, targets TNFR2 and is currently in a Phase I clinical trial. The company is advancing a CD40 antagonist program and plans to file an IND related to that program in 2025. BITT announced a sponsored research and exclusivity agreement with MSRD (part of the Otsuka family) to finance key non-human primate studies for the CD40 program. It was also awarded a $4M grant from the National Institutes of Health/National Cancer Institute to support the ongoing TNFR2 trial. BITT is developing additional antibodies against TNF superfamily receptors for indications in oncology, inflammation, autoimmunity, and infectious disease. Boston Immune Technologies and Therapeutics (BITT) develops antagonist antibodies targeting TNF superfamily receptors, with a lead monoclonal antibody BIR2101 that targets TNFR2. BITT is exploring BIR2101 as monotherapy and in combination with checkpoint blockade, citing preclinical murine models where TNFR2 plus PD‑1 improved cure rates. The company is developing additional discovery-stage TNF superfamily antagonist antibodies, including CD40 antagonists for inflammation and CD30 antagonists for oncology. BITT completed a $10M Series A/A1 preferred stock financing to support clinical development of BIR2101 and other pipeline candidates. The financing, together with an option and license arrangement with BeiGene, aims to enable an IND filing for BIR2101 by the end of 2021 and proof-of-concept studies for additional targets. BITT is based in Boston, MA, and added Lusong Luo of BeiGene and Joseph McMahon to its board.

Total raised

$14M

Funding rounds

2

Latest round

Grant

Latest activity

Aug 2024